RESUMEN
Background: Hemifacial spasm is diagnosed on a clinical base, with certain atypical features alerting the physician for mimics. Phenomenology shown: Hemifacial neuromyotonia/myokymia characterized by tonic hemifacial contraction followed by multifocal undulating hemifacial twitches. Educational value: These features are a red flag for (post-irradiation) facial neuromyotonia/myokymia which generally responds well to low dose carbamazepine.
Asunto(s)
Enfermedades del Nervio Facial , Espasmo Hemifacial , Síndrome de Isaacs , Miocimia , Carbamazepina/uso terapéutico , Enfermedades del Nervio Facial/diagnóstico , Enfermedades del Nervio Facial/etiología , Espasmo Hemifacial/tratamiento farmacológico , Humanos , Síndrome de Isaacs/diagnóstico , Síndrome de Isaacs/tratamiento farmacológico , Miocimia/diagnóstico , Miocimia/tratamiento farmacológicoAsunto(s)
Cannabidiol/administración & dosificación , Movimientos Oculares/fisiología , Miocimia/tratamiento farmacológico , Músculos Oculomotores/fisiopatología , Enfermedades del Nervio Troclear/tratamiento farmacológico , Administración Tópica , Adulto , Anticonvulsivantes/administración & dosificación , Movimientos Oculares/efectos de los fármacos , Humanos , Masculino , Miocimia/etiología , Miocimia/fisiopatología , Enfermedades del Nervio Troclear/complicaciones , Enfermedades del Nervio Troclear/fisiopatologíaRESUMEN
Mutations of the main voltage-gated K channel members Kv1.1 are linked to several clinical conditions, such as periodic ataxia type 1, myokymia and seizure disorders. Due to their role in active magnesium reabsorption through the renal distal convoluted tubule segment, mutations in the KCNA1 gene encoding for Kv1.1 has been associated with hypomagnesemia with myokymia and tetanic crises. Here we describe a case of a young female patient who came to our attention for a history of muscular spasms, tetanic episodes and muscle weakness, initially misdiagnosed for fibromyalgia. After a genetic screening she was found to be carrier of the c.736A > G (p.Asn255Asp) mutation in KCNA1, previously described in a family with autosomal dominant hypomagnesemia with muscular spasms, myokymia and tetanic episodes. However, our patient has always presented normal serum and urinary magnesium values, whereas she was affected by hypocalcemia. Calcium supplementation gave only partial clinical benefit, with an improvement on tetanic episodes yet without a clinical remission of her spasms, whereas magnesium supplementation worsened her muscular symptomatology.
Asunto(s)
Calcio/administración & dosificación , Hipocalcemia , Canal de Potasio Kv.1.1/genética , Magnesio/sangre , Miocimia , Tetania , Adulto , Encéfalo/diagnóstico por imagen , Hormonas y Agentes Reguladores de Calcio/administración & dosificación , Diagnóstico Diferencial , Femenino , Humanos , Hipocalcemia/diagnóstico , Hipocalcemia/etiología , Hipocalcemia/terapia , Imagen por Resonancia Magnética/métodos , Mutación , Miocimia/diagnóstico , Miocimia/tratamiento farmacológico , Miocimia/genética , Miocimia/fisiopatología , Examen Neurológico/métodos , Tetania/diagnóstico , Tetania/tratamiento farmacológico , Tetania/genética , Tetania/fisiopatologíaRESUMEN
BACKGROUND: Since 1994, over 50 families affected by the episodic ataxia type 1 disease spectrum have been described with mutations in KCNA1, encoding the voltage-gated K+ channel subunit Kv1.1. All of these mutations are either transmitted in an autosomal-dominant mode or found as de novo events. METHODS: A patient presenting with a severe combination of dyskinesia and neonatal epileptic encephalopathy was sequenced by whole-exome sequencing (WES). A candidate variant was tested using cellular assays and patch-clamp recordings. RESULTS: WES revealed a homozygous variant (p.Val368Leu) in KCNA1, involving a conserved residue in the pore domain, close to the selectivity signature sequence for K+ ions (TVGYG). Functional analysis showed that mutant protein alone failed to produce functional channels in homozygous state, while coexpression with wild-type produced no effects on K+ currents, similar to wild-type protein alone. Treatment with oxcarbazepine, a sodium channel blocker, proved effective in controlling seizures. CONCLUSION: This newly identified variant is the first to be reported to act in a recessive mode of inheritance in KCNA1. These findings serve as a cautionary tale for the diagnosis of channelopathies, in which an unreported phenotypic presentation or mode of inheritance for the variant of interest can hinder the identification of causative variants and adequate treatment choice.
Asunto(s)
Ataxia/genética , Discinesias/genética , Epilepsia/genética , Canal de Potasio Kv.1.1/genética , Miocimia/genética , Ataxia/diagnóstico , Ataxia/tratamiento farmacológico , Ataxia/patología , Canalopatías/diagnóstico , Canalopatías/tratamiento farmacológico , Canalopatías/genética , Canalopatías/patología , Niño , Preescolar , Discinesias/diagnóstico , Discinesias/tratamiento farmacológico , Discinesias/patología , Epilepsia/diagnóstico , Epilepsia/tratamiento farmacológico , Epilepsia/patología , Femenino , Regulación de la Expresión Génica/efectos de los fármacos , Homocigoto , Humanos , Lactante , Recién Nacido , Canal de Potasio Kv.1.1/ultraestructura , Masculino , Mutación/genética , Miocimia/diagnóstico , Miocimia/tratamiento farmacológico , Miocimia/patología , Oxcarbazepina/administración & dosificación , Oxcarbazepina/efectos adversos , Linaje , Secuenciación del ExomaRESUMEN
While the world reputation of Michel Jouvet in sleep research is based on his huge work on sleep and paradoxical sleep, especially in cats, a far less-known part of his activity was dedicated to investigate and take care of patients with neurological diseases. Indeed, he was also a physician, specialized in neurophysiology and working at the neurological hospital of Lyon. He was most interested first in patients with disorders of consciousness and secondly in those with sleep/wake disorders, and especially in modafinil for the treatment of patients with narcolepsy and idiopathic hypersomnia.
Asunto(s)
Estimulantes del Sistema Nervioso Central/uso terapéutico , Trastornos de Somnolencia Excesiva/tratamiento farmacológico , Modafinilo/uso terapéutico , Narcolepsia/tratamiento farmacológico , Neurólogos , Neurofisiología , Animales , Gatos , Competencia Clínica , Historia del Siglo XX , Historia del Siglo XXI , Humanos , Masculino , Miocimia/tratamiento farmacológico , Trastornos del Sueño-Vigilia/tratamiento farmacológicoRESUMEN
Superior oblique myokymia (SOM) is an uncommon condition of unclear etiology that results in episodes of oscillopsia and diplopia. There is no established treatment protocol for SOM. We present 2 cases of SOM successfully managed with topical levobunolol 0.5%; both patients responded to a short course of medication administration and required minimal ongoing therapy. Case 1 was a 69-year-old woman with left SOM who had previously undergone a left Harada-Ito procedure. Her SOM improved immediately on administration of levobunolol and was maintained at follow-up 1 year later. Case 2 was a 49-year-old man with right SOM that affected his ability to work. After 2 days of topical levobunolol 0.5% nightly in the right eye, SOM episodes ceased; he continues to use drops intermittently for occasional recurrences.
Asunto(s)
Antagonistas Adrenérgicos beta/uso terapéutico , Levobunolol/uso terapéutico , Miocimia/tratamiento farmacológico , Simpaticolíticos/uso terapéutico , Enfermedades del Nervio Troclear/tratamiento farmacológico , Anciano , Femenino , Humanos , Masculino , Persona de Mediana Edad , Resultado del TratamientoRESUMEN
IMPORTANCE: Autoantibodies against contactin-associated protein-like 2 (CASPR2) are observed in several neurological syndromes, including neuromyotonia (NMT), Morvan syndrome (MoS), and limbic encephalitis. OBJECTIVE: To characterize the clinical and biological presentations of patients with anti-CASPR2 antibodies in the cerebrospinal fluid (CSF). DESIGN, SETTING, AND PARTICIPANTS: We conducted a retrospective cohort analysis of 18 patients who had anti-CASPR2 antibodies in their CSF between March 2009 and November 2015 at the Centre National de Référence pour les Syndromes Neurologiques Paranéoplasiques in Lyon, France. Additionally, we analyzed 15 patients who were diagnosed as having NMT or MoS as a comparative group. MAIN OUTCOMES AND MEASURES: Clinical presentations, anti-CASPR2 antibodies specificities, brain magnetic resonance imaging, and CSF analyses, cancer prevalence, and evolution. RESULTS: In this cohort of 18 patients with anti-CASPR2 antibodies in their CSF, 17 (94.4%) were male and had a median (range) age of 64.5 (53-75) years; in the second group, 9 of 15 patients (60.0%) with NMT or MoS were male and had a median (range) age of 51 years (1 month to 75 years). Only 3 patients (16.7%) in this cohort had a previous or concomitant history of cancer (prostate, hematological, or thyroid), whereas 9 patients (60.0%) in the second group had a malignant thymoma. Symptoms of limbic encephalitis were observed in all patients, including temporal lobe seizures in 16 patients (88.9%) and memory disorders in 17 patients (94.4%) from the cohort. Extralimbic signs were also evident in 12 of 18 patients (66.7%), including cerebellar ataxia in 6 patients (33.3%). Only 2 patients (11.1%) from the cohort were diagnosed as having NMT. Brain magnetic resonance imaging displayed T2-weighted temporolimbic abnormalities in 14 of 15 patients (93.3%) in the second group. Cerebrospinal fluid analysis was abnormal in 9 of 12 patients (75.0%). For 16 of 18 patients (88.9%), follow-up was performed for at least a 6-month period (median [range], 34 [11-114] months). Of these, 15 (93.8%) improved and 6 (37.5%) relapsed. In all patients in this cohort, IgG4 autoantibodies were detected in the CSF. Anti-CASPR2 antibodies in the CSF targeted the laminin G1 and discoidin domains of CASPR2 in all patients. Importantly, anti-CASPR2 antibodies were detected in the serum but not in the CSF of all patients with NMT or MoS. CONCLUSIONS AND RELEVANCE: In this cohort study, anti-CASPR2 antibodies in the CSF are associated with a subtype of autoimmune encephalitis with prominent limbic involvement and seizures that is rarely associated with cancer. Conversely, patients with NMT and MoS have anti-CASPR2 antibodies only in the serum but not in the CSF and frequently present with a malignant thymoma. The anti-CASPR2 antibodies found in these patients targeted the discoidin and laminin G1 domains of CASPR2 and always included IgG4 autoantibodies.
Asunto(s)
Autoanticuerpos/líquido cefalorraquídeo , Encefalitis Límbica/líquido cefalorraquídeo , Proteínas de la Membrana/inmunología , Proteínas del Tejido Nervioso/inmunología , Convulsiones/líquido cefalorraquídeo , Anciano , Femenino , Estudios de Seguimiento , Francia , Humanos , Síndrome de Isaacs/líquido cefalorraquídeo , Síndrome de Isaacs/diagnóstico por imagen , Síndrome de Isaacs/tratamiento farmacológico , Encefalitis Límbica/complicaciones , Encefalitis Límbica/diagnóstico por imagen , Encefalitis Límbica/tratamiento farmacológico , Imagen por Resonancia Magnética , Masculino , Persona de Mediana Edad , Miocimia/líquido cefalorraquídeo , Miocimia/diagnóstico por imagen , Miocimia/tratamiento farmacológico , Estudios Retrospectivos , Convulsiones/complicaciones , Convulsiones/diagnóstico por imagen , Convulsiones/tratamiento farmacológico , Esteroides/uso terapéuticoRESUMEN
CASE DESCRIPTION A 5-year-old castrated male Maltese was evaluated for intermittent clinical signs of muscle cramping and abnormal movements of the skin of the right pelvic limb at the site where an infiltrative lipoma had twice been resected. After the second surgery, the surgical field was treated with radiation therapy (RT). The clinical signs developed approximately 14 months after completion of RT. CLINICAL FINDINGS When clinical signs were present, the right biceps femoris and semitendinosus muscles in the area that received RT were firm and had frequently visible contractions, and the skin overlying those muscles had episodic vermiform movements. Electromyography of those muscles revealed abnormal spontaneous activity with characteristics consistent with myokymic discharges and neuromyotonia. Magnetic resonance imaging of the affected leg revealed no evidence of tumor regrowth. The myokymia and neuromyotonia were considered secondary to RT. TREATMENT AND OUTCOME 4 U of Clostridium botulinum toxin type A (BoNT-A) neurotoxin complex was injected into the affected muscles at each of 6 sites twice during a 24-hour period (ie, 48 U of BoNT-A were administered). The clinical signs were completely resolved 10 days after BoNT-A treatment and were controlled by repeated BoNT-A treatment every 3 to 4 months for > 1 year. CLINICAL RELEVANCE To our knowledge, this is the first report of myokymia and neuromyotonia secondary to RT in a dog. For the dog of this report, injection of BoNT-A into the affected muscles was safe, effective, and easy to perform.
Asunto(s)
Toxinas Botulínicas Tipo A/uso terapéutico , Enfermedades de los Perros/tratamiento farmacológico , Síndrome de Isaacs/veterinaria , Miocimia/veterinaria , Fármacos Neuromusculares/uso terapéutico , Traumatismos por Radiación/veterinaria , Animales , Toxinas Botulínicas Tipo A/administración & dosificación , Enfermedades de los Perros/etiología , Perros , Electromiografía/veterinaria , Inyecciones Intralesiones/veterinaria , Inyecciones Intramusculares/veterinaria , Síndrome de Isaacs/tratamiento farmacológico , Síndrome de Isaacs/etiología , Masculino , Miocimia/tratamiento farmacológico , Miocimia/etiología , Fármacos Neuromusculares/administración & dosificación , Traumatismos por Radiación/tratamiento farmacológicoAsunto(s)
Enfermedades Desmielinizantes/tratamiento farmacológico , Furanos/uso terapéutico , Cetonas/uso terapéutico , Miocimia/tratamiento farmacológico , Polineuropatías/tratamiento farmacológico , Adulto , Enfermedades Desmielinizantes/complicaciones , Femenino , Humanos , Miocimia/complicaciones , Polineuropatías/complicacionesRESUMEN
Complex neurologic phenotypes are inherently difficult to diagnose. Whole-exome sequencing (WES) is a new tool in the neurologist's diagnostic armamentarium. Whole-exome sequencing can be applied to investigate the "diagnostic odyssey" cases. These cases involve patients with rare diseases that likely have a genetic etiology but have failed to be diagnosed by clinical evaluation and targeted gene testing. We describe such a case, a 22-year-old man who had mild intellectual developmental disability and episodes of jerking ataxic movements that affected his whole body. He underwent numerous multidisciplinary and multicentric evaluations throughout his life that failed to establish a clear diagnosis. Following his visit to Mayo Clinic in Jacksonville, Florida, WES was applied for genetic determination of the unknown disorder in the proband and his biological parents and sister. Additional clinical evaluation, magnetic resonance neuroimaging, electromyography, and electroencephalography of the proband were performed to verify the phenotype after the WES results were available. To our knowledge, this is the first report of the application of WES to facilitate the diagnosis of episodic ataxia type 1. This case illustrates that WES supported by clinical data is a useful and time-saving tool in the evaluation of patients with rare and complex hereditary disorders.
Asunto(s)
Ataxia/genética , Exoma , Secuenciación de Nucleótidos de Alto Rendimiento , Miocimia/genética , Acetazolamida/uso terapéutico , Anticonvulsivantes/uso terapéutico , Ataxia/tratamiento farmacológico , Secuencia de Bases , Electroencefalografía , Electromiografía , Predisposición Genética a la Enfermedad , Humanos , Imagen por Resonancia Magnética , Masculino , Mutación Missense , Miocimia/tratamiento farmacológico , Linaje , Fenotipo , Adulto JovenRESUMEN
We describe a patient presenting with a combination of muscle fasciculations, paresthesias, hyperhidrosis, as well as insomnia, agitation and confusion. He went on to develop psychosis and respiratory failure requiring intensive care. Electromyography confirmed the presence of neuromyotonia and CSF showed mild pleocytosis. Routine testing for voltage-gated potassium channel complex (VGKC-complex) antibodies was highly positive, confirming the clinical diagnosis of Morvan's syndrome. The patient improved after treatment with intravenous immunoglobulin and methylprednisolone. Further investigation of the antigenic targets using immunohistochemistry and cell-based assays revealed that he had autoantibodies targeting Lgi1, Caspr2 and Contactin-2/Tag-1, all proteins known to be complexed with VGKC in peripheral nerves and CNS. This is the first case of Morvan's syndrome from Cyprus and illustrates the clinical features as well as the emerging complexity of antigenic targets involved in the pathogenesis.
Asunto(s)
Autoanticuerpos/sangre , Síndrome de Isaacs/inmunología , Miocimia/inmunología , Canales de Potasio con Entrada de Voltaje/inmunología , Anciano , Autoanticuerpos/biosíntesis , Contactina 2/inmunología , Humanos , Péptidos y Proteínas de Señalización Intracelular , Síndrome de Isaacs/tratamiento farmacológico , Masculino , Proteínas de la Membrana/inmunología , Miocimia/tratamiento farmacológico , Proteínas del Tejido Nervioso/inmunología , Proteínas/inmunologíaRESUMEN
The clinical and clinicopathological characteristics, treatment and outcome of vermicular muscle contractions (myokymia) and generalized muscle stiffness (neuromyotonia) in 37 Jack Russell terriers were evaluated retrospectively. Thirty dogs were affected by both disorders, whereas seven were presented with myokymia and never developed neuromyotonia. Clinical signs started at the mean age of 8 months. Except for signs of myokymia and neuromyotonia, clinical and neurological examination was normal in all dogs. Thirty dogs demonstrated typical signs of hereditary ataxia. Changes in serum chemistry included increased creatine kinase, aspartate aminotransferase and alanine aminotransferase concentrations. Electromyographic abnormalities, especially in muscles showing macroscopically visible myokymia, consisted of semirhythmic bursts of doublet, triplet, or multiplet discharges of a single motor unit. The amplitudes varied between 80 µV and 1 mV and occurred with an interburst frequency between 10 and 40 Hz and an intraburst frequency between 150 and 280 Hz. Most dogs were treated with a sodium channel blocker with variable results. Seven dogs died (most likely because of hyperthermia) or were euthanased during a neuromyotonic attack; 15 dogs were euthanased due to worsening of clinical signs, or lack of or no long-lasting effect of medication, and three were euthanased for unknown or unrelated reasons. Nine dogs were lost to follow-up and three were still alive 5-10.5 years after the start of clinical signs. In conclusion, young Jack Russell terriers with myokymia and neuromyotonia should undergo a complete blood and electrophysiological examination. Long-term prognosis is not favourable.
Asunto(s)
Enfermedades de los Perros/tratamiento farmacológico , Enfermedades de los Perros/patología , Síndrome de Isaacs/veterinaria , Miocimia/veterinaria , Animales , Bélgica , Análisis Químico de la Sangre/veterinaria , Perros , Electromiografía/veterinaria , Femenino , Estudios de Seguimiento , Síndrome de Isaacs/tratamiento farmacológico , Síndrome de Isaacs/patología , Masculino , Miocimia/tratamiento farmacológico , Miocimia/patología , Estudios Retrospectivos , Resultado del TratamientoRESUMEN
Myokymia is an uncommon neuromuscular disorder that rarely affects the human larynx. No previous reports of isolated laryngeal myokymia are present in the literature, and as such, established treatment protocols are lacking. We report the first case of isolated laryngeal myokymia in a 48-year-old woman with no other neurological findings, and our successful results in initial treatment and maintenance therapy with focal intralaryngeal injections of botulinum toxin A.
Asunto(s)
Toxinas Botulínicas Tipo A/uso terapéutico , Enfermedades de la Laringe/diagnóstico , Enfermedades de la Laringe/tratamiento farmacológico , Miocimia/diagnóstico , Miocimia/tratamiento farmacológico , Fármacos Neuromusculares/uso terapéutico , Diagnóstico Diferencial , Femenino , Humanos , Persona de Mediana EdadRESUMEN
Morvan syndrome is a rare autoimmune disease named after the French physician Augustin Marie Morvan. It is characterized by multiple, irregular contractions of the long muscles, weakness, pruritus, hyperhidrosis, insomnia, and delirium. Here, we describe a 17-year-old young man, previously diagnosed with B-cell lymphoma, who presented with multiple asynchronous fasciculations of the long muscles of his lower extremities accompanied by numbness. The patient responded initially to pulse corticosteroids with diminution of the fasciculations. He achieved complete remission following 7 consecutive, monthly intravenous immunoglobulin injections. The present case is described in the context of the available literature.
Asunto(s)
Linfoma de Células B/complicaciones , Músculo Esquelético/fisiopatología , Miocimia/inmunología , Miocimia/fisiopatología , Adolescente , Autoanticuerpos/biosíntesis , Autoanticuerpos/sangre , Electrodiagnóstico/métodos , Fasciculación/inmunología , Fasciculación/fisiopatología , Humanos , Hiperestesia/inmunología , Hiperestesia/fisiopatología , Inmunoglobulinas Intravenosas/uso terapéutico , Linfoma de Células B/diagnóstico , Masculino , Metilprednisolona/uso terapéutico , Calambre Muscular/inmunología , Calambre Muscular/fisiopatología , Músculo Esquelético/inervación , Miocimia/tratamiento farmacológico , Conducción Nerviosa/inmunología , Nervios Periféricos/inmunología , Nervios Periféricos/patología , Nervios Periféricos/fisiopatología , Quimioterapia por Pulso/métodos , Trastornos del Inicio y del Mantenimiento del Sueño/inmunología , Trastornos del Inicio y del Mantenimiento del Sueño/fisiopatología , Resultado del TratamientoRESUMEN
A nine-year-old male Maltese dog was presented with an eight-month history of inspiratory stridor leading to exertional dyspnoea and cyanosis. Myokymic contractions in the palatolingual muscles were noticed and confirmed by electromyography. Brain computer tomography-scan showed ventricular dilatation. Cerebrospinal fluid analysis revealed a slightly elevated protein level. Treatment with slow-release phenytoin was unsuccessful and symptoms gradually worsened over the next nine months. At post-mortem examination a small pituitary adenoma was found. Apart from a single canine report of facial myokymia, this is the only other description of spontaneous focal myokymia in animals. Palatolingual myokymia has only been reported in one human being. Although the co-occurrence with a pituitary adenoma might be incidental, a paraneoplastic pathogenetic mechanism is proposed. Its unique clinical presentation adds a new, albeit uncommon, syndrome to the differential diagnosis of upper airway complaints in dogs.
Asunto(s)
Enfermedades de los Perros/diagnóstico , Músculos Faciales/inervación , Músculos Faciales/fisiopatología , Miocimia/veterinaria , Animales , Anticonvulsivantes/uso terapéutico , Enfermedades de los Perros/tratamiento farmacológico , Perros , Electromiografía/veterinaria , Resultado Fatal , Masculino , Miocimia/diagnóstico , Miocimia/tratamiento farmacológico , Fenitoína/uso terapéuticoRESUMEN
Morvan's syndrome is a rare disease characterized by peripheral nerve hyperexcitability, associated with CNS and autonomic systems involvement. High serum voltage-gated potassium channel (VGKC) antibody titers have been reported, and, till now, Morvan's syndrome has been considered as a VGKC antibody associated disease. We describe a patient with Morvan's syndrome associated with myasthenia gravis and a thymoma in his previous history, with surprisingly undetectable levels of VGKC antibodies. The clinical course is similar to those cases of Morvan's syndrome with VGKC-Ab, except for the lack of response to plasma exchange, previously considered as the first choice treatment. Nevertheless, the good response to corticosteroids therapy and the association with myasthenia confirm an autoimmune origin of the disease.